

05/17/04

1648

Docket No. 2976-4054US2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Collisson, et al.

Group Art Unit: 1648

Serial No.: 09/303,510

Examiner: Winkler, U.

Filed: April 30, 1999

For: NUCLEIC ACIDS ENCODING FELINE CD86
(Formerly Entitled: FELINE CD80, FELINE CD86, FELINE CD28, AND FELINE
CTLA-4 NUCLEIC ACIDS AND POLYPEPTIDES)

EXPRESS MAIL CERTIFICATE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Express Mail Label No.: EV 357796718 US

Mailing Date: May 6, 2004

I hereby certify that the following attached paper(s) and/or fee

1. Supplemental Information Disclosure Statement (3 pages);
2. Form PTO-1449 (1 page) and all cited references;
3. European Search Report with Communication dated 09.02.2004; and
4. Return receipt postcard.

is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated above and is addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.


Albert Isles

(Typed or printed name of person mailing paper(s) and/or fee)

(Signature of person mailing paper(s) and/or fee)

Correspondence Address:

MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, NY 10154-0053
(212) 758-4800 Telephone
(212) 751-6849 Facsimile



Docket No. 2976-4054US2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Collisson, et al.

Group Art Unit: 1648

Serial No.: 09/303,510,

Examiner: Winkler, U.

Filed: April 30, 1999

For: NUCLEIC ACIDS ENCODING FELINE CD86
(Formerly Entitled: FELINE CD80, FELINE CD86, FELINE CD28, AND FELINE
CTLA-4 NUCLEIC ACIDS AND POLYPEPTIDES)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

This Supplemental Information Disclosure Statement is filed in accordance with 37 C.F.R. §§1.56, 1.97 and 1.98. The items listed on Form PTO-1449, a copy of which is enclosed, are made of record to assist the Patent and Trademark Office in its examination of this application. The Examiner is respectfully requested to fully consider the items and to independently ascertain their teaching.

1. ☐ For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, an English language translation of that item or a portion thereof or a concise explanation of the relevance of that item is enclosed:
2. ☐ For each of the following items listed on the enclosed copy of Form PTO-1449 that is not in the English language, a concise explanation of the relevance of that item is incorporated in the specification of the above-identified application.
3. ☐ Any copy of the items listed on the enclosed copy of Form PTO-1449 that is not enclosed with this Information Disclosure Statement was previously cited by or submitted to the Patent and Trademark Office in application Serial No. _____, filed _____.

4. ☒ No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with:
- ☐ 37 C.F.R. §1.97(b)(1), within three months of the filing date of a national application other than a CPA; or
 - ☐ 37 C.F.R. §1.97(b)(2), within three months of the date of entry into the national stage as set forth in §1.491 in an international application; or
 - ☐ 37 C.F.R. §1.97(b)(3), before the mailing date of a first Office action on the merits; or
 - ☒ 37 C.F.R. §1.97(b)(4) before the mailing date of a first office action after the filing of an RCE under §1.114.
5. ☐ No fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specified in paragraph 4 above but before the mailing date of a final action or a Notice of Allowance (where there has been no prior final action), and is accompanied by one of the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 below.
6. ☐ A fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(c), after the period specified in paragraph 4 above but before the mailing date of a final action or a notice of allowance (where there has been no prior final action):
- ☐ A check in the amount of \$180.00 is enclosed in payment of the fee.
 - ☐ Charge the fee to Deposit Account No. 13-4500, Order No. _____. A
DUPLICATE COPY OF THIS SHEET IS ATTACHED.
7. ☐ A fee is due under 37 C.F.R. §1.17(p) for this Information Disclosure Statement since it is being filed in compliance with 37 C.F.R. §1.97(d), after the mailing date of a final action or a notice of allowance, whichever comes first, but before payment of the issue fee, and is accompanied by:
- a. one of the certifications pursuant to 37 C.F.R. §1.97(e) set forth in paragraph 9 below; and
 - b. the fee due under 37 C.F.R. §1.17(p) which is paid as set forth in paragraph 11 below.
8. ☐ This Information Disclosure Statement is being filed in compliance with:
- a. ☐ 37 C.F.R. §1.313(b)(3) or §1.313(c)(1), after the issue fee has been paid and information cited in this Information Disclosure Statement may render at least one claim unpatentable and is accompanied by the attached Petition To Withdraw Application From Issue and fee pursuant to 37 C.F.R. §1.17(h);

- b. ☐ 37 C.F.R. §1.313(c)(2) or §1.313(c)(3), after the issue fee has been paid and information cited in this Information Disclosure Statement is to be considered in a Request for Continued Examination (RCE) or a Continuation application upon abandonment of the instant application and is accompanied by the attached Petition To Withdraw Application From Issue and fee pursuant to 37 C.F.R. §1.17(h).
- c. ☐ The fee due under 37 C.F.R. §§1.17(h) is paid as set forth in paragraph 11 below.
9. ☒ I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement.
- ☐ I hereby certify that no item of information in the Information Disclosure Statement filed herewith was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this Information Disclosure Statement.
10. ☒ This document is accompanied by ☒ a Search Report ☐ Communication which was cited in a corresponding ☐ PCT or ☒ Foreign counterpart application.
11. ☐ A check in the amount of \$ _____ is enclosed in payment of the fees due under 37 C.F.R. §§1.17(h) and 1.17(p).
- ☐ Charge the fees due under 37 C.F.R. §§1.17(h) and 1.17(p) to Deposit Account No. 13-4500, Order No. _____. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.
- ☒ The Commissioner is hereby authorized to charge any additional fees which may be required for this Information Disclosure Statement, or credit any overpayment to Deposit Account No. 13-4500, Order No. 2976-4054US2. A DUPLICATE COPY OF THIS SHEET IS ATTACHED.

Respectfully submitted,

MORGAN & FINNEGAN, L.L.P.



Evelyn M. Kwon

Registration No. 54,246

Dated: May 6, 2004

Correspondence Address:

MORGAN & FINNEGAN, L.L.P.
345 Park Avenue
New York, NY 10154-0053
(212) 758-4800 Telephone
(212) 751-6849 Facsimile



FORM PTO-1449 INFORMATION DISCLOSURE CITATION	Attorney Docket: 2976-4054US2	Serial No.: 09/303,510
	Applicant: Collisson, et al.	
	Filing Date: April 30, 1999	Group Art Unit: 1648

U.S. PATENT DOCUMENTS

Examiner Initial	Patent Number	Issue Date	Name	Class	Sub-Class	Filing Date

FOREIGN PATENT DOCUMENTS

Examiner Initial	Patent Number	Publication Date	Country	Class	Sub-Class	Translation
	WO 95/03408	02.02.95	PCT	C12N	15/12	<input type="checkbox"/> Yes <input type="checkbox"/> No
	WO 99/47558	23.09.99	PCT	C07K	14/00	<input type="checkbox"/> Yes <input type="checkbox"/> No
	WO 99/57295	11.11.99	PCT	C12N	15/86	<input type="checkbox"/> Yes <input type="checkbox"/> No
						<input type="checkbox"/> Yes <input type="checkbox"/> No
						<input type="checkbox"/> Yes <input type="checkbox"/> No

OTHER DOCUMENTS (Including Author, Title, Date, etc.)

		Maher, S. E. "Porcine Endothelial CD86 Is a Major Costimulator of Xenogeneic Human T Cells," <u>Journal of Immunology</u> , Vol. 157, No. 9, pp 3828-3844, November 1, 1996.
		Isono, T. et al. "Cloning and sequencing of the rabbit gene encoding T-cell costimulatory molecules," <u>Immunogenetics</u> , Vol. 42, No. 3 pp 217-220, 1995.
		Freeman, G.J. "Murine B7-2, an Alternative CTLA4 Counter-receptor that Costimulates T Cell Proliferation and Interleukin 2 Production," <u>The Journal of Exp. Med.</u> , Vol. 178, No. 6, pp 2185-2192, December 1, 1993.
		Maeda, K. et al. "Characterization of rat CD80 and CD86 by molecular cloning and mAb" <u>Int'l. Immunology</u> , Vol. 9, No. 7, pp. 993-1000, July 7, 1997.
		Choi, I-S et al., "Mechanisms of Interaction between FIV infected and FIV effector T. Lymphocytes," <u>Dissertation</u> , Texas A&M University, pp. 1-119 December 1998.
		Choi, I-S et al. "Sequence analyses of feline B7 costimulatory molecules" <u>Veterinary Immunology and Immunopathology</u> , Vol. 73, No. 3-4 pp. 219-231, March 15, 2000.
		Nishimura, Y. et al., "Molecular cloning of the cDNAs encoding the feline B-lymphocyte activation antigen B7-1 (CD80) and B7-2 (CD86) homologues which interact with human CTLA4-Ig," <u>European Journal of Immunogenetics</u> , Vol. 27, No. 5-6, pp. 427-430, October 2000.
		Database WPI Section Ch, Week 199804, Derwent Publications Ltd., London, GB; Class B04, AN 1998-037055, XP00226603.

Examiner	Date Considered
----------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP §609.
Draw line through citation if not in conformance and not considered.
Include copy of this form with next communication to Applicant.